Business Standard

Sun Pharma: Strong Q1 show, settlement of antitrust case pleases investors

Lack of pricing pressure, especially in the US, and debt reduction are other positives

Sun Pharma
Premium

Sun Pharma is the largest player in India’s pharma market, with about 8 per cent market share

Devangshu Datta New Delhi
A strong Q1, 2021-22 (Apr-Jun 2021) performance saw the share price of Sun Pharma jump by 10 per cent in a single session. The pharma major had terrific year-on-year (YoY) results, boosted by the low base of Q1, 2020-21. But it also had a pretty good quarter-on-quarter (QoQ) performance versus Jan-Mar 2021 (Q4, 2020-21).

The consolidated results saw operational revenues climbing to Rs 9,719 crore versus Rs 7,585 crore YoY and versus Rs 8,522 crore QoQ. Sales grew by double-digits YoY in all of its major markets. The PAT (ignoring associates and joint ventures) was registered at Rs 1,404 crore

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jul 30 2021 | 8:27 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com